Valuation: TTY Biopharm Company Limited

Market Cap 19.97B 627M 560M 522M 474M 893M 60.61B 900M 6.28B 2.45B 30.82B 2.35B 2.3B 99.09B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 19.97B 627M 560M 522M 474M 893M 60.61B 900M 6.28B 2.45B 30.82B 2.35B 2.3B 99.09B EV / Sales 2026 *
2.83x
EV / Sales 2027 * -
Free-Float
78.69%
Yield 2026 *
-
Yield 2027 * -
1 day+0.64%
Current month+0.38%
1 month+2.34%
3 months+0.77%
6 months+7.07%
Current year-3.31%
1 week 78.2
Extreme 78.2
79.1
1 month 76.5
Extreme 76.5
79.3
Current year 71.6
Extreme 71.6
87
1 year 71.6
Extreme 71.6
87
3 years 66.2
Extreme 66.2
87
5 years 66.2
Extreme 66.2
88.5
10 years 54.2
Extreme 54.2
131.5
Manager TitleAgeSince
Chief Executive Officer - 18/04/2022
Director of Finance/CFO - 31/12/2015
Compliance Officer - 18/04/2022
Director TitleAgeSince
Director/Board Member - 24/07/1995
Director/Board Member - 24/06/2016
Director/Board Member 70 24/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
+0.64%0.00%+0.13%+1.42% 627M
+2.70%+2.73%+40.91%+110.31% 1,060B
+1.44%-2.38%+36.83%+63.95% 623B
+1.75%+3.73%+16.55%+83.05% 480B
+0.60%-1.73%+62.98%+37.46% 352B
-1.39%+1.43%+21.52%+41.12% 345B
-1.05%+0.37%+11.27%+34.46% 274B
-0.97%-2.05%-5.88%+10.80% 249B
+2.60%-2.00%+39.77%+54.44% 223B
+1.82%-1.48%+25.75%+96.48% 182B
Average -0.40%-0.40%+24.98%+53.35% 378.86B
Weighted average by Cap. -0.44%+0.04%+31.41%+70.15%

Financials

2026 *2027 *
Net sales 7.05B 221M 198M 184M 167M 315M 21.39B 318M 2.21B 865M 10.88B 830M 812M 34.97B -
Net income - -
Net Debt - -
Projected Income Statement - Annual - TTY Biopharm Company Limited
Logo TTY Biopharm Company Limited
TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
07/10/26 NT$80.30 +1.90% 1,430,696
06/10/26 NT$78.80 +0.64% 674,504
05/10/26 NT$78.30 -0.76% 376,466
02/10/26 NT$78.90 +0.51% 314,185
01/10/26 NT$78.50 0.00% 449,424
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - TTY Biopharm Company Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
80.30TWD
Average target price
92.00TWD
Spread / Average Target
+14.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - TTY Biopharm Company Limited
  1. Stock Market
  2. Stocks
  3. 4105 Stock